Bleeding Disorders Treatment Market Expected to Grow at a CAGR of 8.4% to Reach $23.04 billion by 2026 – Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristol-Myers Squibb Company, Cangene
Bleeding Disorders Treatment Market is accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026. Factors like growth in R&D investment for hemophilia products, inclination towards prophylactic treatment, increasing number of hemophilia patients, and the emergence of Biosimilars product are fuelling the market growth. Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth. Market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products. However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.
By type, Hemophilia is a genetic disorder characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII or IX deficiency. Patients with more severe haemophilia suffer more severe and more frequent bleeds. Hemophilia is inherited in an X-linked recessive manner. The main therapy to treat hemophilia A is concentrated FVIII product, as clotting factor or simply factor. DDAVP (desmopressin acetate) is the synthetic version of vasopressin, a natural antidiuretic hormone that helps stop bleeding. Emerging trends in therapies are efficacy and safety assessments of established extended half-life (EHL) factor products and interest in Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies.
Get Sample PDF For More Professional And Technical Insights at: https://www.premiummarketinsights.com/sample/SMRC00015910
Some of the key players in Global Bleeding Disorders Treatment Market are Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristol-Myers Squibb Company, Cangene Corporation, CSL Behring, Grifols SA, Janssen Pharmaceuticals, Novo Nordisk A/S, Octapharma, Pfizer Inc., Sanofi and Xenetic Biosciences, Inc.
Based on Drug, Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. There are a few clotting factor concentrates that are rich in VWF. The management of patients affected by rare bleeding disorders (RBDs) is still a critical challenge. The development of alternative therapeutics, such as anti-tissue factor pathway inhibitor, ALN-AT3, and ACE910, for patients with hemophilia might also help in the treatment of patients affected by RBDs. FDA approved Vonvendi, which is produced with a genetically engineered Chinese hamster ovary cell line that expresses von Willebrand factor and the blood-clotting protein factor VIII.
North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.
– Fibrin Sealants
– Plasma-derived Coagulation Factor Concentrates
– Recombinant Coagulation Factor Concentrates
– Other Drugs
– Hemophilia A
– Hemophilia B
– Von Willebrand Disease
– Clotting Factor Deficiency
– Medication Treatments
– Replacement Therapies
Get Complete Report at: https://www.premiummarketinsights.com/buy/SMRC00015910
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
About Premium Market Insights:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.